Dose-escalated intensity modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study published in the April 1, 2014 edition of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Previous randomized clinical trials have shown that dose-escalated radiation therapy improves prostate cancer control compared to lower-dose conventional radiation therapy. Conventional fractionation of dose-escalated radiation therapy (1.8 or 2 Gy fractions) can take up to nine weeks to complete, while hypofractionated radiation therapy can deliver a higher biologically effective dose over a shorter period of time (six weeks) and has the potential to increase prostate cancer control without increasing toxicity.
However, there are limited data on the late toxicity of moderate hypofractionated regimens for prostate cancer. This randomized trial from the University of Texas MD Anderson Cancer Center compares the late toxicity outcomes of men with localized prostate cancer treated with either conventionally fractionated IMRT (CIMRT) or dose-escalated hypofractionated IMRT (HIMRT).
Men with organ-confined prostate cancer were enrolled in this institutional review board-approved trial from January 2001 to January 2010 and were randomized to receive either CIMRT (75.6 Gy in 1.8 Gy fractions over eight-and-a-half weeks) or HIMRT (72 Gy in 2.4 Gy fractions over six weeks). Eligible patients had biopsy-proven prostate adenocarcinoma; good performance status; stage T1b-T3b disease; a prostate-specific antigen (PSA) ≤20 ng/ml; a Gleason score <10; and no clinical, radiographic or pathologic evidence of nodal or bone metastasis.
Patients with stage cT3c or cT4 disease, a history of prior pelvic radiation therapy, or who received more than four months of hormone ablation therapy with prior or planned radical prostate surgery and with concurrent active malignancy other than nonmetastatic skin cancer or early-stage chronic lymphocytic leukemia were not eligible for the trial. The median age of the patient cohort was 68. Of the 203 patients analyzed in the study, 72 percent had stage T1 disease (146) and 89 percent had a PSA <10 ng/ml (181). Thirty-four percent (70) had Gleason 6 disease, 65 percent (131) had Gleason 7 disease and 1 percent (2) had Gleason 8 disease. Patients were classified into low-risk (28 percent = 57), intermediate risk (71 percent = 144) and high-risk (1 percent = 2) disease using current National Comprehensive Cancer Network risk-group definitions.
All patients were treated with static-field IMRT. One hundred and one (101) men received CIMRT and 102 men received HIMRT. Physician-reported toxicity was evaluated for all patients during treatment and at each follow-up visit. After completion of radiation therapy, follow-up was conducted at least every six months for the first two years post-treatment, and annually thereafter. Median follow-up was six years.
Late gastrointestinal (GI) and genitourinary (GU) toxicity were analyzed in this study, starting 90 days post-treatment, using modified Radiation Therapy Oncology Group toxicity grading. In the CIMRT arm, 17 percent (17) experienced grade 1 GI toxicity, 4 percent (4) experienced grade 2 GI toxicity and 1 percent (1) experienced grade 3 GI toxicity. In the HIMRT arm, 26 percent (27) experienced grade 1 GI toxicity, 9 percent (9) experienced grade 2 GI toxicity and 2 percent (2) experienced grade 3 GI toxicity. There was a numeric increase in the absolute frequency of late GI toxicity for men treated with HIMRT, but the difference was not statistically significant. The five-year actuarial grade 2 or 3 late GI toxicity was 5.1 percent (95 percent Confidence Interval (CI)) for patients treated with CIMRT and 10 percent for patients treated with HIMRT. The increase in late GI toxicity for men receiving HIMRT was the result of moderate and high radiation dose to a larger proportion of the rectum, which suggests that more stringent dose constraints for the rectum may result in lower late GI toxicity for those patients.
Additionally, there was not a statistically significant difference in the absolute frequency of late GU toxicity in men treated with CIMRT or HIMRT. In the CIMRT arm, 15 percent (15) experienced grade 1 GU toxicity, 14 percent (14) experienced grade 2 GU toxicity and 1 percent (1) experienced grade 3 GU toxicity. In the HIMRT arm, 10 percent (10) experienced grade 1 GU toxicity and 15 percent (15) experienced grade 2 GU toxicity; no patients reported grade 3 GU toxicity. The five-year actuarial grade 2 or 3 late GU toxicity was 16.5 percent (95 percent CI) for patients treated with CIMRT and 15.8 percent for patients treated with HIMRT.
“These results demonstrate that the length of radiation treatment for prostate cancer can be safely decreased to six weeks (from eight-and-a-half weeks) by delivering larger daily doses of radiation without increasing the urinary and bowel effects,” said Karen E. Hoffman, MD, a co-author of the study and assistant professor in the Division of Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston. “Decreasing the length of treatment decreases the cost and is more convenient for patients.”
Brittany Ashcroft | EurekAlert!
Subaru Telescope helps pinpoint origin of ultra-high energy neutrino
16.07.2018 | National Institutes of Natural Sciences
Nano-kirigami: 'Paper-cut' provides model for 3D intelligent nanofabrication
16.07.2018 | Chinese Academy of Sciences Headquarters
For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.
To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...
For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.
Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...
Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.
A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...
Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.
"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....
Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.
Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...
13.07.2018 | Event News
12.07.2018 | Event News
03.07.2018 | Event News
16.07.2018 | Physics and Astronomy
16.07.2018 | Life Sciences
16.07.2018 | Earth Sciences